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Summary
Background: There is a known shortfall in hepatology service resources across Eng-
land and Wales.
Aim: To investigate early and late mortality following unscheduled admissions for
severe liver disease, overall and by cause of death, and to determine how mortality
is related to admissions to transplant centres, transplant surgery, hospital size, con-
sultant specialty, patient socio‐demographics, seasonal and geographical factors.
Methods: Cohorts of people with a first unscheduled admission for severe liver dis-
ease across England and Wales from 2004, based on record linkage of national inpa-
tient and mortality data.
Findings: Mortality for alcoholic liver disease and hepatic failure was 23.4% and
35.4% respectively at 60 days and 61.8% and 57.1% at 5 years. Standardised mor-
tality ratios (SMRs) were extremely high at 60 days (184 and 117 respectively) and
remained highly increased at 5 years (16.7 and 6.3). Mortality at 5 years was most
elevated from liver disease, viral hepatitis and varices. The 60‐day mortality was sig-
nificantly lower for patients seen by consultant hepatologists and gastroenterolo-
gists. Both early and late mortality were significantly reduced for patients admitted
to transplant centres or larger hospitals, who received a liver transplant, or were res-
ident in London. Early mortality was significantly higher for patients admitted in win-
ter and autumn, while elevated mortality among the most vs least deprived quintile
increased with longer follow‐up.
Conclusions: The study shows a very poor prognosis for people with unscheduled
hospitalisation for severe liver disease. The findings suggest that access to specialist
expertise and services improves survival, both in the short and long term.
The Handling Editor for this article was Professor Stephen Harrison, and it was accepted
for publication after full peer‐review.
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1 | INTRODUCTION
There is a known shortfall in specialist liver services resources
across the UK,1–3 which has led to the establishment of a Lancet
Commission on liver disease.2,4–7 A number of other studies have
reported on late mortality following hospitalisation for severe liver
disease,8–22 and how it varies according to the cause of
death,9,14,20,21 with much of the evidence from Scandi-
navia.9,12,15,16,19,21,22 Little has been reported on how early and late
mortality are associated with possibly important service and socio‐
demographic factors.
The main objectives of this study were, firstly, to establish early
and late mortality following unscheduled admission for severe liver
disease across England and Wales, both overall and by cause of
death. The second main objective was to establish how early and
late mortality are associated with admissions to transplant centres,
liver transplantation, the hospital size, consultant specialty, patient
socio‐demographics, seasonal factors and the geographical region of
England and Wales.
To provide confirmatory evidence, the study was based on two
independently run UK National Health Services for which similar but
separate data have been collected across England and Wales. The
main study hypotheses were firstly, that mortality for severe liver
disease would be very high, with greatly increased mortality from
infections, liver cancer, accidents and suicide as well as from liver
disease itself. Further hypotheses were, that mortality would be
greatly reduced following liver transplantation; that early mortality
would be improved for patients managed by trained hepatologists or
gastroenterologists rather than by other specialists and by admission
to specialist centres; and that late mortality would be worse for
patients with the highest levels of social deprivation.
2 | MATERIALS AND METHODS
The study was based on retrospective cohorts of people admitted
unscheduled for severe liver disease across England and Wales. The
first cohort, to investigate early mortality, included each person's
first admission for severe liver disease from the start of the study in
January 2004 to October 2012 with 60‐day follow‐up to the end of
2012. The second cohort, to investigate late mortality, included each
person's first admission for severe liver disease from January 2004
to the end of 2007 with 5‐year follow‐up to the end of 2012.
The study cohorts were based on national administrative inpa-
tient data, Hospital Episode Statistics for England (population 53.5
million in 2012) and the corresponding Patient Episode Database for
Wales (population 3.07 million). The inpatient data were linked sys-
tematically to mortality data from the Office for National Statistics
and the Welsh Demographic Service to identify deaths that occurred
while in hospital or after discharge from hospital. The data were
compiled and accessed through the Secure Anonymised Information
Linkage (SAIL) databank.23,24 The ascertainment of mortality has
been validated as > 98% accurate and the record linkage
methodology, based on a unique anonymised, encrypted linking field
for each patient, as > 99.8% accurate.23
Severe liver disease was defined as alcoholic liver disease (Inter-
national Classification of Diseases, ICD, 10th revision code, K70) or
hepatic failure (K72) when based on the principal diagnosis on the
discharge episode. Alcoholic liver disease was also differentiated
according to the three aetiologies, alcoholic hepatitis (K70.1), alco-
holic liver cirrhosis (K70.3) and alcoholic hepatic failure (K70.4).
2.1 | Study exposure factors
Mortality was compared according to whether patients were admit-
ted to one of the six hospitals in England in which liver transplant
centres were located, in Birmingham, Cambridge, Leeds, London (2
centres) and Newcastle.1 For patients admitted to transplant centres,
we also assessed mortality according to whether or not they were
local patients, defined as resident in the same local authorities in
which the transplant centres were located. We also assessed mortal-
ity according to whether patients received a liver transplant (OPCS
Classification of Interventions and Procedures, OPCS‐4 code J01) in
their index cohort admission.
The size of the admitting hospital was categorised by the total
number of beds in five bands from < 400, 400‐599, 600‐799, 800‐
999 to 1000+ beds). Consultant specialty was based, firstly, on
whether or not the patients were seen by a hepatologist or gas-
troenterologist and compared with all other specialties (recorded
during either the first or last episodes of the admission). Secondly,
on whether, the patients were seen by a critical care specialist, com-
pared with all other specialties. The season of admission was
assessed by comparing winter months (December to February) with
autumn (September to November), summer (June to August) and
spring (March to May) as the reference category.
Social deprivation was measured using the widely used English
Indices of Multiple Deprivation (IMD) for England,25 and the similar
Welsh Index of Multiple Deprivation (WIMD) for Wales.26 The total
IMD and WIMD deprivation scores for geographical Lower Super
Output Areas (LSOAs) (average LSOA population = 1640 in England
and 1580 in Wales) were ranked and categorised into quintiles (I =
least deprived and V = most deprived quintile).
The regions of England and Wales were based on the patients’
recorded residence and the conventional Government Office Regio-
nal classification which includes 10 regional categories.27 Namely,
these are London, South East of England, South West of England,
East of England, West Midlands, East Midlands, Yorkshire and Hum-
berside, North West of England, North East of England, and Wales.
2.2 | Outcome measures
The main outcome measures were ‘early mortality’, defined as all
deaths within 60 days of admission and ‘late mortality’, all deaths
within 5 years of admission. Secondary outcome measures were
standardised mortality ratios (SMRs) at 60 days and 5‐year follow‐up
and also relative survival at monthly intervals up to 5 years. They
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were used to compare mortality in the cohorts of patients hospi-
talised for severe liver disease with those in the corresponding gen-
eral populations of England and Wales. Cause‐specific SMRs at 5‐
year follow‐up were based on the underlying causes of death on
death certificates.
2.3 | Methods of analysis
Age and sex adjusted SMRs were calculated using the indirect
method, by applying age and sex specific mortality in the general
adult resident populations of England of Wales to obtain the
expected mortality and by then comparing observed and expected
mortality. The age groups used were 18‐19 years, 20‐24, quinquen-
nially up to 80‐84 and then 85+ years. Relative survival was calcu-
lated as a ratio to compare the observed survival in the cohorts of
patients hospitalised for severe liver disease with that expected in
the corresponding (age‐ and sex‐matched) general populations of
England and Wales.
Multivariate logistic regression models were used to assess asso-
ciations between the study exposure factors and subsequent mortal-
ity. In the models, mortality was adjusted for patient age (in 5‐year
groups from 35 to 85+ years, with < 35 years as the reference cate-
gory), sex and 10 major patient co‐morbidities (ischaemic heart dis-
ease, other cardiovascular diseases, cerebrovascular disease, other
circulatory diseases, malignancies, chronic obstructive pulmonary dis-
ease (COPD), asthma, diabetes, renal failure and dementia; ICD‐10
codes are listed for each co‐morbidity in the Appendix A). The co‐
morbidities were based on a diagnosis recorded in any position on
the patients' current inpatient record or on previous inpatient
records during the preceding 5 years. To eliminate any possible
biases in the determination of patient co‐morbidities from inpatient
admissions alone, adjustment was also made for patients with no
previous admissions during the preceding 5 years. Patient sex was
missing in < 0.01% of cases (5 of 73 123), postcode‐based social
deprivation in 2.3% (1668), consultant specialty in < 0.01% (15), resi-
dential local authority in 4.1% of patients admitted to liver transplant
centres (110 of 2653) and hospital size (coded only at trust level;
18.5%, 13 531). Missing data were excluded from the analyses
involving the respective factors. There were no missing data for
patient age, residential region, admissions to transplant centres,
cause of death and day of admission or death.
Additionally, through record linkage of the inpatient data, we
identified subsequent emergency admissions for severe liver disease
in the study cohort patients and compared survival according to the
numbers of subsequent admissions. When assessing trends in early
mortality for alcoholic liver disease and for hepatic failure, annual
mortality rates were standardised using the direct method and the
total populations of patients admitted as the standard populations.
Logistic regression modelling was used to obtain mean annual reduc-
tions over time in the age and sex adjusted early mortality rates for
alcoholic liver disease and hepatic failure. Other methods used were
unpaired t tests to compare patient ages, chi‐squared tests to com-
pare patient co‐morbidities and socio‐demographics and the Mann‐
Whitney test to compare lengths of inpatient stay. Statistical signifi-
cance was measured at the conventional 5% level.
3 | RESULTS
In the first study cohort with 60‐day follow‐up to investigate early
mortality, there were a total of 73 123 patients hospitalised with
severe liver disease; mean age = 52.8 years (SD = 12.7) and 35.3%
were female. In the second cohort with 5‐year follow‐up to establish
late mortality, there were a total of 33 726 patients; mean
age = 52.5 years (SD = 12.2) and 35.0% were female.
3.1 | Early and late mortality
For England and Wales combined, early 60‐day mortality (cohort 1)
for alcoholic liver disease and hepatic failure was 23.4% and 35.4%
respectively (Table 1). Late 5‐year mortality was respectively 61.8%
and 57.1% (cohort 2). When comparing mortality with the corre-
sponding general resident populations of England and Wales, SMRs
were higher throughout follow‐up for alcoholic liver disease than for
hepatic failure, they were extremely high at 60‐day follow‐up (184
for alcoholic liver disease and 117 for hepatic failure, compared with
1.0 in the general population) and remained highly elevated in the
longer term (16.7 for alcoholic liver disease and 6.3 for hepatic fail-
ure at 5 years).
Early survival was substantially worse following admission with
hepatic failure than for alcoholic liver disease, approximately equal
by 3‐year follow‐up, but over longer term follow‐up, it deteriorated
much more severely for alcoholic liver disease (Figure 1A). Of the
three main categories of alcoholic liver disease, prognosis was worst
for alcoholic liver failure, followed by alcoholic liver cirrhosis, but
comparatively better for alcoholic hepatitis (Figure 1B).
Early 60‐day mortality fell significantly over time during the
study period, although this was greater for hepatic failure than for
alcoholic liver disease (Figure 2). The mean annual reduction was
3.4% (95% CI = 1.8%‐5.1%) for hepatic failure and 0.7% (0.0%‐1.4%)
for alcoholic liver disease.
3.2 | Cause‐specific mortality
Table 2 shows cause‐specific mortality (SMRs) for late mortality (5‐
year follow‐up) separately for patients admitted with alcoholic liver
disease or with hepatic failure. At 5 years, liver disease accounted
for 72.2% of all deaths among those originally admitted with alco-
holic liver disease and 51.0% of those admitted with hepatic failure
(Table 2). Late mortality was extremely increased (SMR > 100) from
most of the major causes of death from liver disease and also from
viral hepatitis and varices (although the SMR for varices was lower
at 71.7 in patients admitted for hepatic failure).
Late mortality was also very highly increased (SMRs > 10) from
liver cancer, acute and chronic pancreatitis, septicaemia, infectious
diseases generally, mental and behavioural disorders due to alcohol
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and from accidental poisoning (Table 2). Late mortality was also very
highly increased (SMRs > 10) among patients admitted with alcoholic
liver disease, but not with hepatic failure, from certain gastrointesti-
nal diseases (oesophageal ulcer, perforated peptic ulcer and peritoni-
tis and herniae), accidental falls, mental and behavioural disorders
generally and due to drugs.
There was relatively little or no increased mortality from cancers
overall and from the major types of cancer, with the exceptions of
mouth and throat cancer in people admitted with alcoholic liver dis-
ease (SMR = 7.9) and pancreatic cancer in those admitted with hep-
atic failure (SMR = 5.5; Table 2). Among patients admitted for
hepatic failure, there was little or no increased late mortality from
circulatory diseases generally, ischaemic heart disease, respiratory
diseases generally, COPD and pneumonia.
3.3 | Factors that may influence prognosis
Early 60‐day mortality but not late 5‐year mortality was significantly
lower among patients seen by hepatologists or gastroenterologists
(by 22.3% compared with other specialties; Table 3). Both early and
late mortality were significantly much lower among patients admit-
ted to specialist transplant centres (by 26.5% and 38.6% respec-
tively), who received liver transplants (by 4‐ and 7‐fold respectively;
Table 3; Figure 3) and who were resident in London compared with
all other major regions of England and Wales. Both early and late
mortality were also significantly reduced among patients admitted to
larger compared with smaller hospitals, although this pattern was
stronger for early mortality.
Early but not late mortality was significantly higher among
patients admitted during winter and autumn compared with
other months (Table 3). Among women compared with men,
early mortality was significantly increased (by 6.3%) but late
mortality was reduced (by 10.8%). Mortality was also signifi-
cantly worse among patients with the highest levels of social
deprivation compared with the lowest (quintile V vs I) and this
differential increased from early mortality (9.2%) to late mortal-
ity (21.0%). There were no other significant differences between
deprivation quintiles.
Both early and late mortality were greatly increased among
patients seen by critical care consultants, by 9‐fold and 5‐fold
respectively (Table 3). Compared with all other patients admitted
acutely with severe liver disease, those seen by critical care special-
ists were less often: diagnosed with alcoholic liver disease (73.8% vs
87.9%; P < 0.001), male (59.4% vs 64.8%; P = 0.002), and (non‐sig-
nificantly) socially deprived (54.6% vs 58.3% in the two most
deprived quintiles; P = 0.067) but were of similar ages (mean = 52.2
vs 52.8 years; P = 0.201). They also had longer inpatient stays (me-
dian = 14.0 vs 9.0 days; P < 0.001).
TABLE 1 Early and late mortality rates and standardised mortality ratios (SMRs) following unscheduled admissions for severe liver disease in
England and Wales overall and according to aetiology
Early mortality cohort (60‐d follow‐up) Late mortality cohort (5‐y follow‐up)
No. of
admissions
No. of
deaths
Mortality
(%) SMR (95% CI)
No. of
admissions
No. of
deaths
Mortality
(%) SMR (95% CI)
England and Wales
Severe liver disease 73 123 18 194 24.9 167.2 (176.0, 181.0) 33 726 20 685 62.8 14.3 (14.1, 14.5)
Alcoholic liver disease 64 145 15 014 23.4 184.0 (181.1, 186.9) 30 057 18 590 61.8 16.7 (16.5, 16.9)
Alcoholic hepatitis 10 817 1666 15.4 198.8 (189.3, 208.4) 4318 1994 46.2 20.1 (19.3, 21.0)
Alcoholic liver cirrhosis 16 764 4426 26.4 158.3 (153.7, 163.0) 7118 4917 69.1 14.7 (14.3, 15.2)
Alcoholic liver failure 7155 3267 45.7 356.4 (344.3, 368.7) 2592 2006 77.4 20.2 (19.4, 21.1)
Hepatic failure 8978 3180 35.4 116.8 (112.8, 121.0) 3669 2095 57.1 6.3 (6.0, 6.6)
England
Severe liver disease 68 219 17 014 24.9 168.5 (165.9, 171.0) 31 389 19 217 61.2 14.4 (14.2, 14.6)
Alcoholic liver disease 59 765 14 032 23.5 185.8 (182.7, 188.9) 27 957 17 269 61.8 16.8 (16.6, 17.1)
Alcoholic hepatitis 10 296 1576 15.3 197.5 (187.9, 207.4) 4100 1895 46.2 20.1 (19.2, 21.1)
Alcoholic liver cirrhosis 15 627 4116 26.3 159.7 (154.9, 164.6) 6637 4566 68.8 14.7 (14.3, 15.2)
Alcoholic liver failure 6734 3074 45.6 353.2 (340.8, 365.8) 2457 1893 77.0 20.2 (19.3, 21.1)
Hepatic failure 8454 2982 35.3 117.1 (113.0, 121.4) 3432 1948 56.8 6.3 (6.0, 6.6)
Wales
Severe liver disease 4904 1180 24.1 155.8 (147.5, 164.4) 2337 1468 62.8 14.0 (13.3, 14.7)
Alcoholic liver disease 4380 982 22.4 161.7 (151.8, 172.0) 2100 1321 62.9 16.0 (15.1, 16.9)
Alcoholic hepatitis 521 90 17.3 224.2 (180.4, 273.2) 218 99 45.4 20.2 (16.4, 24.4)
Alcoholic liver cirrhosis 1137 310 27.3 141.6 (126.2, 157.8) 481 351 73.0 13.9 (12.5, 15.4)
Alcoholic liver failure 381 193 50.7 416.5 (359.8, 477.3) 135 113 83.7 20.7 (17.1, 24.7)
Hepatic failure 524 198 37.8 112.7 (95.7, 128.9) 237 147 62.0 6.6 (5.6, 7.7)
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3.4 | Patients admitted to transplant centres
Among patients admitted to transplant centres, both early and late
mortality were substantially higher among those resident locally,
compared with patients admitted from other local authorities
(Table 3). ‘Local’ compared with ‘non‐local’ patients, were of similar
age (52.6 vs 53.0 years respectively; P = 0.425) and gender (33.7%
vs 35.0% women; P = 0.496), but had higher levels of social depriva-
tion (48.4% from the most deprived quintile V vs 19.7%; P < 0.001).
Of the major co‐morbidities, local patients had higher levels of
  Alcoholic liver disease - England
  Alcoholic liver disease - Wales
  Hepatic failure - England
  Hepatic failure - Wales
0.0
0.2
0.4
0.6
0.8
1.0
0.0
0.2
0.4
0.6
0.8
1.0
0 12 24 36 48 60
Relative
survival 
Relative
survival 
Month after admission
0 12 24 36 48 60
Month after admission
  Alcoholic hepatitis - England
  Alcoholic hepatitis - Wales
  Alcoholic liver cirrhosis - England
  Alcoholic liver cirrhosis - Wales
  Alcoholic liver failure - England
  Alcoholic liver failure - Wales
(A) (B)
F IGURE 1 Relative survival up to 5 y following unscheduled admissions for severe liver disease in England and Wales, compared with the
corresponding age‐ and sex‐matched general populations. A, Alcoholic liver disease and hepatic failure. B, Alcoholic hepatitis, alcoholic liver
cirrhosis and alcoholic liver failure. Shaded areas represent 95% CIs
0
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20
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40
2004 2005 2006 2007 2008 2009 2010 2011 2012
Mortality at 60 d (%) 
Year of admission
  Alcoholic liver disease
  Hepatic failure
F IGURE 2 Trends in early (60‐d)
mortality for alcoholic liver disease and
hepatic failure in England and Wales.
Mortality rates are standardised for age
group and sex. Vertical bars represent 95%
CIs
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TABLE 2 Underlying causes of death and corresponding SMRs at 5 y following unscheduled admissions for alcoholic liver disease and
hepatic failure in England and Wales
Underlying cause of death ICD‐10 codes
Alcoholic liver disease Hepatic failure
No. of
deaths
(% of all
deaths) SMR (95% CI)
No. of
deaths
(% of all
deaths) SMR (95% CI)
Gastrointestinal diseases K00‐K93 13 886 (74.7) 184.3 (181.2, 187.4) 1164 (55.6) 66.4 (62.6, 70.2)
Liver disease K70‐K77 13 429 (72.2) 333.2 (327.6, 338.8) 1068 (51.0) 239.6 (225.4, 254.2)
Alcoholic liver disease K70 10 861 (58.4) 378.3 (371.2, 385.4) 497 (23.7) 184.5 (168.7, 201.1)
Hepatic failure K72 170 (0.9) 271.3 (232.1, 313.6) 117 (5.6) 1068.3 (883.5, 1270.6)
Other liver disease K71, K73‐K77 2398 (12.9) 218.6 (210.0, 227.5) 454 (21.7) 274.3 (249.7, 300.1)
Fibrosis & cirrhosis of
liver
K74 1651 (8.9) 247.2 (235.5, 259.3) 328 (15.7) 336.2 (300.8, 373.6)
Non‐alcoholic hepatic
steatosis
K76.0 71 (0.4) 45.9 (35.9, 57.3) 29 (1.4) 169.2 (113.2, 236.4)
Portal hypertension K76.6 14 (0.1) 317.2 (184.3, 485.9) * * 213.8 (20.2, 612.8)
Hepato7renal
syndrome
K76.7 89 (0.5) 492.1 (395.2, 599.6) * * 173.3 (33.8, 358.4)
Other gastrointestinal
diseases
K00‐K67, K80‐
K93
457 (2.5) 13.0 (12.0, 14.3) 96 (4.6) 7.3 (5.9, 8.8)
Oesophageal and gastric
varices
I85, I86.4 24 (0.1) 130.2 (83.3, 187.4) * * 71.7 (6.8, 205.6)
Oesophageal ulcer K22.1 20 (0.1) 41.0 (25.0, 60.9) * * 9.6 (0.0, 37.8)
Perforated peptic ulcer &
peritonitis
K25‐K27, K65 170 (0.9) 21.1 (18.6, 25.1) 16 (0.8) 6.7 (3.8, 11.4)
Herniae K40‐K43, K45,
K46
20 (0.1) 14.9 (9.1, 22.1) * * 3.8 (0.4, 11.0)
Intestinal obstruction K56 12 (0.1) 4.3 (2.2, 7.2) * * 0.8 (0.0, 3.0)
Diverticular disease K57 16 (0.1) 6.7 (3.8, 10.4) * * 3.1 (0.8, 7.0)
Acute pancreatitis K85 44 (0.2) 15.7 (11.4, 20.7) 10 (0.5) 14.8 (7.1, 25.4)
Chronic pancreatitis K86.0, K86.1 26 (0.1) 35.7 (23.3, 50.8) * * 12.5 (0.0, 48.8)
Cancers C00‐C96 852 (4.6) 2.1 (2.0, 2.3) 241 (11.5) 2.5 (2.2, 2.8)
Liver cancer C22 316 (1.7) 30.8 (27.5, 34.3) 71 (3.4) 32.6 (25.5, 40.7)
Other gastrointestinal
cancers
C15‐C21, C23‐
C26
124 (0.7) 1.1 (1.0, 1.4) 52 (2.5) 2.0 (1.5, 2.6)
Oesophageal cancer C15 46 (0.2) 1.9 (1.4, 2.5) * * 0.4 (0.0, 1.2)
Gastric cancer C16 6 (0.0) 0.5 (0.2, 0.9) * * 0.3 (0.0, 1.1)
Colorectal cancer C18‐C20 36 (0.2) 1.7 (1.2, 2.3) 16 (0.8) 3.2 (1.9, 2.5) 5.0)
Pancreatic cancer C25 23 (0.1) 1.1 (0.7, 1.6) 27 (1.3) 5.5 (3.6, 7.7)
Other cancers C00‐C14, C30‐
C97
412 (2.2) 1.4 (1.3, 1.6) 118 (5.6) 1.7 (1.4, 2.0)
Mouth and throat
cancer
C00‐C14, C32 88 (0.5) 7.9 (6.3, 9.6) * * 2.8 (0.9, 5.8)
Lung cancer C33, C34 116 (0.6) 1.2 (1.0, 1.4) 15 (0.7) 0.7 (0.4, 1.1)
Breast cancer C50 21 (0.1) 1.0 (0.6, 1.4) 26 (1.2) 4.3 (2.8, 6.1)
Prostate cancer C61 17 (0.1) 0.7 (0.4, 1.0) 10 (0.5) 1.3 (0.6, 2.2)
Lymphomas C81‐C96 15 (0.1) 0.5 (0.3, 0.8) 16 (0.8) 2.1 (1.2, 3.3)
Infectious diseases A00‐B99 314 (1.7) 23.8 (21.3, 26.5) 126 (6.0) 28.8 (24.0, 34.0)
Viral hepatitis B15‐B19 160 (0.9) 123.6 (105.2, 143.5) 93 (4.4) 685.5 (533.3, 831.9)
Septicaemia A40, A41 92 (0.5) 23.8 (19.2, 28.9) 21 (1.0) 14.5 (9.1, 21.4)
Circulatory diseases I00‐I99 1333 (7.2) 4.0 (3.8, 4.2) 239 (11.4) 2.0 (1.7, 2.2)
Ischaemic heart disease I20‐I25 517 (2.8) 2.8 (2.5, 3.0) 109 (5.2) 1.9 (1.6, 2.3)
(Continues)
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COPD (11.3% vs 6.1%; P < 0.001), lower levels of renal failure
(21.5% vs 27.8%; P = 0.006), cancers (8.4% vs 15.5%; P < 0.001)
and diabetes (16.7% vs 22.8%; P < 0.001), but similar levels of
stroke (5.0% vs 4.0%; P = 0.256) and ischaemic heart disease co‐
morbidities (10.4% vs 8.7%; P = 0.157). When compared with locally
resident patients, the diagnosis for patients transferred to transplant
centres from elsewhere was more often for hepatic failure (31.1% of
cases vs 17.9%; P < 0.001), a diagnosis that has a better longer term
prognosis than alcoholic liver disease, and less often for alcoholic
liver failure (3.9% vs 9.3%; P < 0.001) which has the worst prognosis
of the subtypes.
The 140 patients who received liver transplants were mostly not
resident locally (89%), were slightly but not significantly younger
(51.8% vs 52.8%; P = 0.103) and more affluent (14.7% vs 34.9% in
quintile V; P < 0.001) than other patients with severe liver disease.
On admission, they also had higher levels of cancers (20.0% vs 7.3%;
P < 0.001), diabetes (35.0% vs 15.7%; P < 0.001) and renal failure
co‐morbidities (32.1% vs 18.7%; P < 0.001) but lower levels of
COPD (3.6% vs 9.1%; P = 0.024). Of 19 deaths in the 5 years fol-
lowing liver transplantation, alcoholic disorders were not recorded as
a cause of death in a single case.
3.5 | Subsequent admissions for severe liver
disease in the cohort patients
Figure 4 shows relative survival according to the numbers of admis-
sions for severe liver disease. At 5 years, relative survival was signifi-
cantly and substantially better among patients during a first
admission for severe liver disease (40.2%) compared with a second
admission (28.8%) a 3rd (25.4%) or a 4th further admission (23.3%).
4 | DISCUSSION
The study shows a very poor overall prognosis following unsched-
uled hospital admissions for severe liver disease. Mortality was
increased by more than 100‐fold in the short term and remained
highly elevated throughout 5 years of follow‐up. Mortality was most
extremely elevated from liver disease, viral hepatitis and varices.
Early 60‐day mortality was substantially lower for patients seen by
consultant hepatologists or gastroenterologists. Both early and late
mortality were reduced for patients admitted to specialist transplant
centres and larger hospitals, those who received liver transplantation,
or were resident in London. Early mortality was higher for patients
admitted in winter and autumn months, while late mortality was
increased with higher levels of patient social deprivation.
Our findings of high early mortality and very poor long‐term
prognosis for people hospitalised with severe liver disease are con-
cordant with the limited European literature on this subject. For
example, our relative survival at 5 years of 55% for alcoholic hep-
atitis and 32% for alcoholic liver cirrhosis across England and
Wales compares with 53% and 35%, respectively, from a study
from Denmark during 2006 to 2011,21 and 46% and 29% across
Finland from 1996‐2012.22 Our figure of 32% for alcoholic liver
cirrhosis is almost identical to 33% reported across England from
1998‐2009.20.
Long‐term prognosis following admissions for alcoholic liver dis-
ease is known to be very poor, largely since many cases present
with decompensated liver disease when first seen, and subsequent
abstinence rates can be low.8,28 Although early mortality was much
higher for (non‐alcoholic) hepatic failure than for alcoholic liver dis-
ease, by 6 months most of the excess mortality for hepatic failure
TABLE 2 (Continued)
Underlying cause of death ICD‐10 codes
Alcoholic liver disease Hepatic failure
No. of
deaths
(% of all
deaths) SMR (95% CI)
No. of
deaths
(% of all
deaths) SMR (95% CI)
Stroke I61‐I64 271 (1.5) 5.8 (5.1, 6.5) 26 (1.2) 1.1 (0.7, 1.6)
Respiratory diseases J00‐J99 614 (3.3) 5.2 (4.6, 5.4) 62 (3.0) 1.2 (0.9, 1.5)
Pneumonia J12‐J18 216 (1.2) 6.1 (5.2, 6.7) 32 (1.5) 1.6 (1.1, 2.1)
COPD J40‐J44 190 (1.0) 3.5 (3.0, 4.1) 11 (0.5) 0.6 (0.3, 1.0)
Mental and behavioural
disorders
F00‐F99 272 (1.5) 13.7 (12.1, 15.4) 19 (0.9) 1.5 (0.9, 2.3)
Due to alcohol use F10 210 (1.1) 54.8 (47.6, 62.4) 13 (0.6) 35.5 (18.9, 57.5)
Due to drug use F11‐F19 47 (0.3) 15.6 (11.5, 20.4) * * 7.3 (0.7, 21.0)
Injury and poisoning V01‐Y98 517 (2.8) 9.7 (8.9, 10.6) 52 (2.5) 5.4 (4.1, 7.0)
Accidental falls W00‐W19 145 (0.8) 18.9 (15.9, 22.1) 8 (0.4) 3.3 (1.4, 6.1)
Transport accidents V01‐V89 25 (0.1) 3.2 (2.1, 4.6) 0 (0.0) 0
Accidental poisoning X40‐X49 117 (0.6) 21.2 (17.5, 25.2) 18 (0.9) 33.4 (19.8, 50.6)
Homicide X85‐Y09 * (0.0) 3.9 (1.0, 8.7) 0 (0.0) 0
Suicide X60‐X84, Y10‐
Y33.8
80 (0.4) 4.0 (3.2, 4.9) 14 (0.7) 6.8 (3.7, 10.8)
All causes of death A00‐Z99 18 590 (100) 16.7 (16.5, 16.9) 2095 (100) (6.3) (6.0, 6.6)
*Denotes small numbers of cases ≤ 5.
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TABLE 3 Early and late mortality following unscheduled admissions for severe liver disease in England and Wales in relation to consultant
specialty, hospital size, admissions to liver transplant centres, geographical residential region, season and socio‐demographics
Early mortality (60‐d follow‐up) Late mortality (5‐y follow‐up)
No. of
admissions
Mortality rate
(%)
Odds
ratio (95% CI)
No. of
admissions
Mortality rate
(%)
Odds
ratio (95% CI)
Specialty
Gastro/ hepatology 25 978 22.4 Ref 8892 61.2 Ref
Other specialties 47 130 26.3 1.223 (1.177, 1.270) 24 822 61.4 0.988 (0.938, 1.041)
Hospital size (beds)
<400 11 310 25.9 Ref 4438 62.4 Ref
400‐599 22 450 25.6 1.001 (0.947, 1.058) 10 182 62.4 0.993 (0.920, 1.071)
600‐799 13 381 25.0 0.996 (0.937, 1.060) 5983 61.0 0.964 (0.887, 1.048)
800‐999 8966 21.4 0.812 (0.756, 0.871) 3652 58.2 0.874 (0.796, 0.960)
1000+ 3485 23.4 0.884 (0.804, 0.972) 1597 61.1 0.935 (0.827, 1.057)
Admissions to a liver transplant centre
No 70 470 25.9 Ref 32 633 61.7 Ref
Yes 2653 20.5 0.735 (0.664, 0.814) 1093 50.9 0.614 (0.541, 0.697)
Transplant centre admissions
Local patients 1524 22.7 Ref 590 55.4
Non‐local patients 1019 16.7 0.637 (0.509, 0.796) 440 48.4 0.693 (0.527, 0.912)
Liver transplant surgery (during index cohort admission)
Yes 140 7.9 Ref 94 20.2 Ref
No 72 983 24.9 4.037 (2.151, 7.575) 33 632 61.4 7.218 (4.293, 12.14)
Liver transplant surgery
Local patients 15 0.0 Ref 7 14.3 Ref
Non‐local patients 125 8.8 * * 87 20.7 0.763 (0.041, 14.34)
Residential region
London 9736 21.2 Ref 4591 54.9 Ref
South East 8318 26.6 1.291 (1.212, 1.383) 3867 63.5 1.335 (1.218, 1.468)
South West 5908 25.5 1.221 (1.144, 1.324) 2677 63.2 1.276 (1.152, 1.414)
East of England 5536 24.7 1.257 (1.163, 1.350) 2614 60.8 1.213 (1.094, 1.343)
East Midlands 5006 25.7 1.284 (1.199, 1.398) 2279 62.2 1.296 (1.164, 1.443)
West Midlands 7816 27.8 1.466 (1.355, 1.549) 3597 62.6 1.398 (1.274, 1.535)
Yorkshire &
Humber
7300 25.3 1.359 (1.274, 1.462) 3292 61.9 1.350 (1.227, 1.485)
North East 4682 24.2 1.300 (1.200, 1.404) 2140 61.0 1.324 (1.187, 1.477)
North West 13 811 24.3 1.333 (1.251, 1.409) 6316 62.3 1.473 (1.358, 1.597)
Wales 5010 24.0 1.236 (1.152, 1.354) 2353 62.8 1.369 (1.231, 1.522)
Season admitted
Spring 18 455 24.0 Ref 8434 61.1 Ref
Summer 18 977 23.8 0.994 (0.945, 1.045) 8686 60.3 0.980 (0.919, 1.045)
Autumn 18 464 25.6 1.091 (1.038, 1.148) 8280 61.9 1.040 (0.975, 1.110)
Winter 17 227 26.3 1.128 (1.072, 1.187) 8326 62.0 1.029 (0.964, 1.098)
Patient age group
18‐35 5123 10.5 Ref 2217 35.1 Ref
35‐44 14 414 15.6 1.702 (1.537, 1.884) 6945 51.0 1.922 (1.738, 2.124)
45‐54 21 565 21.8 2.618 (2.375, 2.885) 10 250 59.5 2.793 (2.533, 3.079)
55‐64 19 101 28.6 3.838 (3.480, 4.232) 8728 65.5 3.944 (3.565, 4.363)
(Continues)
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had arisen, whereas longer term survival for alcoholic liver disease
continued to deteriorate much more sharply. Of the three main cate-
gories of alcoholic liver disease investigated, both early and late mor-
tality were poorest for alcoholic liver failure, reflecting end‐stage liver
disease in many cases. Although early mortality for alcoholic hepatitis
aetiology was high, longer term prognosis was relatively good. Also, it
has been reported that a sub‐diagnosis of alcoholic hepatitis improves
survival in patients with compensated alcoholic liver cirrhosis.13
Nonetheless, especially in studies based on national administrative
inpatient data, there would be variations in definitions and case
detection, and also some misclassification of aetiologies. For example,
the high SMR from alcoholic liver disease mortality (as the underlying
cause of death) for patients admitted with hepatic failure suggests
misclassification in some cases. Both alcoholic hepatitis and alcoholic
liver failure are more likely to present with more detectable symp-
toms than compensated alcoholic liver cirrhosis. Without a biopsy, it
can also be difficult to distinguish cases of alcoholic hepatitis from
decompensated cirrhosis due to alcohol.
Mortality for both alcoholic liver disease and hepatic failure at
5 years was elevated most extremely (>100 and up to 1068‐fold
increased risk) from liver disease, viral hepatitis and varices; followed
by liver cancer, accidental poisoning, alcohol misuse disorders and,
for alcoholic liver disease admissions, oesophageal ulcer, chronic
pancreatitis, septicaemia and accidental falls. These findings are simi-
lar to those from a large national study of alcoholic liver disease
across Finland which reported slightly worse prognosis overall.22 For
example, our cause‐specific 5‐year SMRs and those reported from
Finland are respectively: all causes of death (England and Wales,
SMR = 16.7; Finland, 19.9), injury and poisoning (9.7; 11.1), acciden-
tal falls (18.9; 20.2), suicide (4.0; 5.0), homicide (3.9; 13.0), circulatory
diseases (4.0; 6.1), respiratory diseases (5.2; 7.9), infectious diseases
(23.8; 21.0), all cancers (2.1; 6.8) and liver cancer (30.8; 79.0). Our
finding of low and/or non‐significant SMRs from non‐liver cancers
and from other causes of death that are usually associated with
older age groups is partly because of the very high mortality in peo-
ple with severe liver disease that occurs prematurely in younger and
middle age groups. Although acute viral hepatitis infections (A, B, C
and E) cause mortality, the extremely high SMR for viral hepatitis is
probably attributable more to cirrhosis arising from chronic hepatitis
B or C infections.
Both early and late mortality were greatly reduced for patients
admitted to specialist transplant centres or resident in London and
early mortality was also substantially lower for patients seen by con-
sultant hepatologists or gastroenterologists compared with other
specialties. As reported previously,1–4 there is both a shortfall and a
higher concentration of transplant centres and hepatology resources
in London than in other regions of England and Wales, while liver
disease care has been shown to be inadequate in many non‐special-
ist centres.2,3 Consequently, mortality rates vary considerably across
hospitals.2 Our findings provide further strong evidence that access
to specialist resources and expertise improves prognosis.
The finding of lower mortality in largest compared with smaller
or non‐specialist hospitals, which is consistent with findings from the
Lancet Commission into liver disease,2 would also reflect differences
in access to expertise, experience and services, relating to hospital
size. However, patients who were transferred to transplant centres
from elsewhere often had better prognosis (with proportionately
more cases of hepatic failure and fewer of alcoholic liver failure),
suggesting that there may be selection of cases for transfer based
on prognosis. Both early and late mortality were also greatly reduced
TABLE 3 (Continued)
Early mortality (60‐d follow‐up) Late mortality (5‐y follow‐up)
No. of
admissions
Mortality rate
(%)
Odds
ratio (95% CI)
No. of
admissions
Mortality rate
(%)
Odds
ratio (95% CI)
65‐74 9267 36.3 5.745 (5.179, 6.372) 3988 76.9 7.003 (6.215, 7.890)
75+ 3653 51.8 10.91 (9.695, 12.27) 1598 87.6 14.26 (11.97, 16.99)
Patient sex
Male 47 317 24.6 Ref 21 904 62.2 Ref
Female 25 801 25.5 1.063 (1.024, 1.103) 11 820 59.6 0.892 (0.850, 0.936)
Social deprivation
I 7719 27.6 Ref 3455 62.9 Ref
II 9884 27.1 1.002 (0.933, 1.077) 4481 62.6 1.016 (0.923, 1.119)
III 12 270 25.5 0.997 (0.931, 1.068) 5516 62.5 1.090 (0.994, 1.195)
IV 16 693 24.3 1.020 (0.956, 1.089) 7745 60.8 1.085 (0.995, 1.183)
V 24 889 23.7 1.092 (1.026, 1.162) 11 711 61.6 1.210 (1.114, 1.315)
Specialty
Critical care
medicine
749 76.1 Ref 212 89.2 Ref
Other specialties 72 374 24.4 0.111 (0.093, 0.133) 33 514 61.2 0.197 (0.127, 0.306)
Ref = comparison reference category.
*Denotes zero mortality so that a logistic regression model cannot be applied.
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in patients who received liver transplantation and this reduction
widened with longer term follow‐up.
As expected, both early and late mortality were greatly increased
in patients seen by critical care specialists. The highest mortality in
winter months may also be linked to access as resources become
more strained in winter due to increases in admissions for seasonal
illnesses, although it may also reflect seasonal variation in alcohol
consumption.
We found that late but not early mortality was significantly worse
among patients with higher levels of social deprivation and also in
Wales compared with England overall. This would reflect more general
social inequalities in health,29,30 and have previously been reported
for severe liver disease,16,28 with increases in equalities over the
longer term rather than soon after hospital admission and treatment.
4.1 | Strengths and limitations
Major strengths are that this study is national, one of the largest
investigations on prognosis following admission for severe liver dis-
ease and it provides new evidence on factors that influence both
early and late mortality. The study uses systematic validated record
linkage methodology that has been used extensively in previous pub-
lications and it covers more than 70 000 admissions for severe liver
disease and over 20 000 subsequent deaths. Importantly for confir-
matory purposes, it is based on independently collected but similar
information sources covering two different populations. The inpa-
tient data sources are based on public hospitals, but these would
account for almost all unscheduled admissions for severe liver dis-
ease in the two populations.
Limitations are that the national administrative inpatient data
used in this study lack detailed information about disease history,
disease severity, any therapeutic treatments and also alcohol con-
sumption. Although the study cohorts are based solely on each
patient's first admission for severe liver disease during the study per-
iod, the information sources do not provide adequate details of how
they relate to any possible long‐term previous history of liver dis-
ease. We assessed patients who received liver transplants during
their study admissions, but were not able to identify from our data
patients who subsequently received transplants electively. The prin-
cipal diagnosis used to determine admissions for severe liver disease
is also not accurate in all cases,31 while our investigations of the
subtypes and aetiologies of severe liver disease and the subsequent
causes of deaths are also constrained by the limitations of the ICD
coding inherent in national administrative data.
In administrative inpatient data, the consultant specialty managing
and treating patients is available only for the first and last episodes of
the admission, and the specialties classified do not distinguish
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hepatology separately from gastroenterology. However, this should
still have enabled ascertainment of most of the patients who were
managed by hepatologists, gastroenterologists or critical care special-
ists. Late 5‐year mortality would also be affected by cohort attrition,
mainly through population emigration. However, emigration from Eng-
land and Wales was less than 2.8% per annum during the study per-
iod,32,33 and it would probably be substantially lower among people
with severe liver disease than among the general population. For these
reasons, and also since our findings are similar to those from previous
cohort studies,20–22 cohort attrition should be small.
In summary, the study shows a very poor prognosis for people
admitted unscheduled for severe liver disease, and several factors
that are strongly associated with survival both in the short and long
term. In the longer term, prognosis for (non‐alcoholic) hepatic failure
is considerably better than for alcoholic liver disease. The study sug-
gests that better access to expertise and specialist services improves
survival, both in the short and long term.
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APPENDIX A
TABLE 4 ICD‐10 codes used for the patient co‐morbidities
Ischaemic heart disease (120‐I25)
Other cardiovascular diseases (I00‐I15, I26‐I52)
Cerebrovascular disease (I60‐I69)
Other circulatory diseases (I70‐I99)
Malignancies (C00‐C97)
COPD (J40‐J44)
Asthma (J45, J46)
Diabetes (E10‐E14)
Renal failure (N17‐N19)
Dementia (F00‐F03, F05.1, G30)
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